Revisiting 2-Substituted-4(1H)-Quinolones for Targeting the Plasmodium falciparum Cytochrome bc₁ Complex

Area of Science:

• Medicinal Chemistry
• Parasitology
• Drug Discovery

Background:

• Quinolones are investigated for antimalarial potential, with ELQ-300 (a 3-position diphenyl ether) in advanced preclinical development.
• The 2-position isomer of ELQ-300, HLQ-102, presents an opportunity to explore structure-activity relationships and alternative synthetic routes.

Purpose of the Study:

• To synthesize HLQ-102, the 2-position isomer of ELQ-300, using cost-effective methods.
• To evaluate the antimalarial activity and pharmacokinetics of HLQ analogs.
• To investigate the binding site and cross-resistance patterns of HLQ-102.

Main Methods:

• Synthesis of substituted quinolones, including HLQ-102, avoiding expensive catalysts.
• Antimalarial activity profiling of HLQ analogs.
• Pharmacokinetic analysis of a lead HLQ molecule.
• Cross-resistance studies to determine the drug target.

Main Results:

• Successful synthesis of HLQ-102 and related substituted quinolones with a 3-position CH3 group.
• HLQ analogs demonstrated antimalarial activity.
• Cross-resistance patterns confirmed that HLQ-102 targets the Qi site of the parasite cytochrome bc1 complex.

Conclusions:

• HLQ-102 is a viable 2-position quinolone analog with antimalarial potential.
• The parasite cytochrome bc1 complex exhibits flexibility, accommodating large structural features at either the 2- or 3-position of the quinolone ring.
• This suggests broader possibilities for designing novel antimalarial drugs targeting the Qi site.